ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Article: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleDr. Nathalie Johnson Calls for Medical Community to Move to Action for Equality in Genomic Testing for Black Women
Dr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her opinion in STAT News article on why Black women with breast cancer experience higher death rates and how utilizing a more advanced genomic test can provide a more comprehensive understanding and accurate risk evaluation.
Read the ArticleHIT Consultant: Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, recently spoke with HIT Consultant about why the conventional genomic test commonly used for breast cancer treatment planning is failing Black women, and in part, contributing to their disproportionately high mortality rate. Dr. Johnson discusses why MammaPrint provides more consistent results for Black women than the other gene expression profiling test, enabling more personalized treatment and improved outcomes.
Read the Article
News
Media Releases
MammaPrint® approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.
Read MoreAgendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study
Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform
Read MoreNew Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint
The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia’s advanced genomic assays.
Read MoreAgendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
Read More
